Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).

Shigeru TanzawaTomonori MakiguchiSadatomo TasakaMegumi InabaRyosuke OchiaiJunya NakamuraKoji InoueTakayuki KishikawaMasanao NakashimaKeiichi FujiwaraTadashi KohyamaHiroo IshidaShoichi KuyamaNaoki MiyazawaTomomi NakamuraHiroshi MiyawakiNaohiro OdaNobuhisa IshikawaRyotaro MorinagaKei KusakaYosuke MiyamotoToshihide YokoyamaChiaki MatsumotoTakeshi TsudaSunao UshijimaKazuhiko ShibataTakuo ShibayamaAkihiro BesshoKyoichi KairaToshihiro MisumiKenshiro ShiraishiNoriyuki MatsutaniNobuhiko Seki

Published in: Therapeutic advances in medical oncology (2022)

Japan Registry of Clinical Trials, jRCTs031190127, registered 1 November, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs031190127.

Keyphrases

advanced non small cell lung cancer
locally advanced
clinical trial
epidermal growth factor receptor
rectal cancer
early stage
radiation therapy
spinal cord
squamous cell carcinoma
radiation induced
spinal cord injury
phase ii
tyrosine kinase